Naliri (Onivyde)
Other Medications · Approved since 2015
Description
Naliri (liposomal irinotecan) is a nanoparticle encapsulated formulation of the topoisomerase I inhibitor irinotecan, designed to improve drug delivery and reduce toxicity compared to conventional irinotecan. It is used in combination chemotherapy regimens for metastatic colorectal cancer, particularly in the NALIRIFOX regimen which combines naliri with leucovorin, fluorouracil, and oxaliplatin. This formulation allows for enhanced tumor penetration and prolonged drug exposure while potentially reducing some systemic side effects associated with standard irinotecan.
Mechanism of Action
Naliri works by inhibiting topoisomerase I, an enzyme essential for DNA replication and transcription in rapidly dividing cancer cells. The liposomal encapsulation allows for preferential accumulation in tumor tissue through enhanced permeability and retention effects, leading to sustained release of irinotecan at the tumor site and subsequent DNA damage in colorectal cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Onivyde |
| Category | Other Medications |
 Status | FDA Approved |
| Administration | IV |
| Year Approved | 2015 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.